Zoetis (ZTS) Hisse Özeti
Zoetis Inc. Amerika Birleşik Devletleri'nde ve uluslararası alanda hayvan sağlığı endüstrisi için ilaçların, aşıların, teşhis ürünlerinin ve hizmetlerinin, biyolojik cihazların, genetik testlerin ve hassas hayvan sağlığı çözümlerinin keşfi, geliştirilmesi, üretimi ve ticarileştirilmesi ile ilgilenmektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 5/6 |
| Gelecekteki Büyüme | 2/6 |
| Geçmiş Performans | 4/6 |
| Finansal Sağlık | 3/6 |
| Temettüler | 5/6 |
Ödüller
Risk Analizi
ZTS Community Fair Values
Create NarrativeSee what 201 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$92.92
FV
18.8% değerinin altında içsel indirim4.06%
Revenue growth p.a.
340
users have viewed this narrative4users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
Zoetis Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$74.80 |
| 52 Haftanın En Yüksek Seviyesi | US$161.77 |
| 52 Haftanın En Düşük Seviyesi | US$71.47 |
| Beta | 0.75 |
| 1 Aylık Değişim | -5.84% |
| 3 Aylık Değişim | -35.96% |
| 1 Yıllık Değişim | -52.37% |
| 3 Yıllık Değişim | -56.06% |
| 5 Yıllık Değişim | -62.29% |
| Halka arzdan bu yana değişim | 141.21% |
Son Haberler & Güncellemeler
Seeking Alpha • Jul 05
Zoetis: The 60% Decline Was Justified, But Shares Are Finally Buyable
Summary Zoetis has seen its valuation compress dramatically, now trading at just 12x trailing earnings after a 52% 12-month share price decline. Despite decelerating growth—Q1 2026 saw just 3% revenue growth—international and livestock segments are offsetting U.S. pet care weakness. Dividend growth remains robust, with a 12-year streak and a current yield of 2.8% backed by a solid payout ratio. At current levels, ZTS offers a solid risk/reward, with fair value estimates suggesting the potential for 50% upside. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Jun 24
ZTS: Future Pipeline And New Therapies Will Restore Confidence
Zoetis' analyst-derived fair value has been reset from $127.00 to $90.00 as analysts factor in weaker growth assumptions, a lower future P/E, and softer margin expectations following recent price target cuts and downgrades tied to investor confidence and competitive pressures. Analyst Commentary Recent research on Zoetis points to a more cautious mood, with several bearish analysts focusing on valuation pressure, softer execution and questions around the strength of future growth.Analiz Makalesi • Jun 20
Zoetis (ZTS) Stock Could Be 15.3% Undervalued After Class Action Lawsuits
Zoetis (ZTS) is back in focus after a series of securities class action lawsuits accused the company of misleading investors about weakening demand, safety concerns, and market share losses in its key companion animal products. See our latest analysis for Zoetis. At a share price of $78.71, Zoetis has seen pressure build over the past few months, with a 90 day share price return that declined 31.95% and a 1 year total shareholder return that declined 49.14%. Repeated class action...Recent updates
Seeking Alpha • Jul 05
Zoetis: The 60% Decline Was Justified, But Shares Are Finally Buyable
Summary Zoetis has seen its valuation compress dramatically, now trading at just 12x trailing earnings after a 52% 12-month share price decline. Despite decelerating growth—Q1 2026 saw just 3% revenue growth—international and livestock segments are offsetting U.S. pet care weakness. Dividend growth remains robust, with a 12-year streak and a current yield of 2.8% backed by a solid payout ratio. At current levels, ZTS offers a solid risk/reward, with fair value estimates suggesting the potential for 50% upside. Read the full article on Seeking AlphaAnlatı Güncellemesi • Jun 24
ZTS: Future Pipeline And New Therapies Will Restore Confidence
Zoetis' analyst-derived fair value has been reset from $127.00 to $90.00 as analysts factor in weaker growth assumptions, a lower future P/E, and softer margin expectations following recent price target cuts and downgrades tied to investor confidence and competitive pressures. Analyst Commentary Recent research on Zoetis points to a more cautious mood, with several bearish analysts focusing on valuation pressure, softer execution and questions around the strength of future growth.Analiz Makalesi • Jun 20
Zoetis (ZTS) Stock Could Be 15.3% Undervalued After Class Action Lawsuits
Zoetis (ZTS) is back in focus after a series of securities class action lawsuits accused the company of misleading investors about weakening demand, safety concerns, and market share losses in its key companion animal products. See our latest analysis for Zoetis. At a share price of $78.71, Zoetis has seen pressure build over the past few months, with a 90 day share price return that declined 31.95% and a 1 year total shareholder return that declined 49.14%. Repeated class action...
Anlatı Güncellemesi • Jun 10
ZTS: Premium Pet Health Portfolio Will Support Post Selloff Earnings Reset
Analysts have trimmed Zoetis' average price target by roughly $30 to $40 to around the low $100s. This reflects recent target cuts from firms citing softer Q1 results, intensifying competition, and a sharp pullback in the stock that has weighed on investor confidence.Anlatı Güncellemesi • May 26
ZTS: Premium Pet Health Portfolio Will Support Reset Earnings Path Forward
Zoetis' analyst fair value estimate has been reset from $151.00 to about $124.59 as analysts trim price targets after a difficult Q1, rising competitive pressures, and signs that premium pricing is meeting more cautious consumer demand, despite longer term guidance implying improvement. Analyst Commentary Recent research points to a reset in expectations for Zoetis, with target prices broadly trimmed as analysts rework their models around the latest Q1 update, rising competition, and more cautious consumer behavior toward premium products.
Yeni Anlatı • May 26
Zoetis down -50% over the past year
World's leading animal pharma company at 13x PE with 9% EPS growth Occasionally something crosses my eye which screens well, but after some work is done it isn’t interesting enough to warrant writing about it as a paid article. Zoetis is one such stock.
Anlatı Güncellemesi • May 03
ZTS: Share Repurchases And Capital Discipline Will Support Medium-Term Upside
Analysts have modestly trimmed their Zoetis fair value estimate by about $3 to $184, reflecting mixed updates to revenue growth, margins, and long term P/E assumptions after recent shifts in price targets and ratings across the Street. Analyst Commentary Recent research updates on Zoetis reflect a mix of reduced price targets, a downgrade on growth concerns, and fresh bullish coverage.Anlatı Güncellemesi • Apr 19
ZTS: Fair View Weighs Organic Growth Concerns Against Pipeline Execution Risk
Analysts have trimmed the Zoetis fair value estimate by $3 to $127, reflecting a mix of cautious views around organic growth and slightly adjusted assumptions for future P/E, revenue growth, and profitability, even as some firms maintain a bullish stance on the stock. Analyst Commentary Recent Street research around Zoetis shows a split tape, with several bearish analysts focusing on weaker organic growth trends and execution risk, even as others remain constructive on the long term story.Anlatı Güncellemesi • Apr 04
ZTS: Share Repurchases And Execution Recovery Will Support Medium-Term Upside
Analyst targets on Zoetis have shifted modestly, with a small net reduction in the Street price target in dollar terms as some analysts cite concerns about organic growth and an innovation "air pocket," even as others make minor upward adjustments. Analyst Commentary Recent Street research on Zoetis reflects a split view, with some analysts emphasizing concerns around organic growth and an innovation air pocket, while others are adjusting targets in a more constructive way.Anlatı Güncellemesi • Mar 21
ZTS: Future OA Pain Launch And Buybacks Will Support Medium-Term Upside
Narrative Update The updated analyst price target for Zoetis moves from about $197.51 to $187.59, reflecting analysts' mixed views. Some cite softer organic growth and an innovation "air pocket," while others make smaller price target adjustments.Anlatı Güncellemesi • Mar 06
ZTS: Fair View Balances Growth Concerns With Innovation Air Pocket Risk
Zoetis's analyst price target holds steady at $130, as analysts balance concerns about organic growth and an innovation "air pocket" with stable margin expectations and a lower future P/E assumption. Analyst Commentary Recent Street research on Zoetis points to a more cautious tone, with several bearish analysts questioning the near term growth setup and how that lines up with the current valuation.Anlatı Güncellemesi • Feb 20
ZTS: Future Pet Osteoarthritis Pipeline Will Support Premium Multiple Potential
Zoetis' analyst fair value estimate has been reset from $158.22 to $151.00, as analysts balance recent price target changes and a slightly lower assumed future P/E multiple against broadly steady growth and margin assumptions. Analyst Commentary Recent Street research on Zoetis points to a mixed setup, with some analysts seeing support for the current valuation and others focusing on execution risk and the product pipeline.Anlatı Güncellemesi • Feb 06
ZTS: Future OA Pain Launch Execution Will Drive Medium-Term Upside Potential
Analysts have trimmed their Zoetis fair value estimate from about US$200 to roughly US$197.51. This reflects recent price target cuts and more cautious views around product launch headwinds and competition, even as they still see solid margins and a premium P/E as part of the story.Anlatı Güncellemesi • Jan 22
ZTS: Fair Outlook Balances OA Pain Headwinds With New Antibody Approvals
Narrative update on Zoetis The analyst fair value estimate for Zoetis has been reset from US$153 to US$130 as analysts factor in slower expected revenue growth, a slightly higher discount rate, lower assumed future P/E multiples, and ongoing competitive and product launch headwinds highlighted in recent research. Analyst Commentary Recent research on Zoetis has tilted more cautious, with several bearish analysts resetting expectations around growth, execution, and what investors are willing to pay for the stock.Anlatı Güncellemesi • Jan 08
ZTS: Future Product Launches Will Offset Current Competition Pressures
Analysts have trimmed their price targets on Zoetis, reflecting a fair value move from about $170 to $158 as they factor in product launch headwinds, tougher competition in key franchises, and more cautious revenue expectations for 2025 and 2026. Analyst Commentary Recent Street research reflects a mixed but more cautious stance on Zoetis, with several firms trimming price targets and reassessing growth and competitive risks over the next few years.Anlatı Güncellemesi • Dec 15
ZTS: Execution In Animal Health Leadership Will Drive Medium-Term Upside Potential
Analysts have cut their fair value estimate for Zoetis by about $30,000,000,000 to roughly $200,000,000,000, reflecting expectations for slower mid decade revenue growth, modestly lower margins, and a less generous future earnings multiple amid increasing competitive and product launch headwinds. Analyst Commentary Recent Street research reflects a more balanced stance on Zoetis, with fair value expectations reset lower but many firms still highlighting the company as a structural leader in animal health.Anlatı Güncellemesi • Nov 30
ZTS: Earnings Will Recover As Competition Pressures Recent Product Launches
Zoetis's fair value target experienced a modest reduction to $169.96. Analysts highlighted competitive pressures and headwinds from recent product launches as key drivers for the change.Anlatı Güncellemesi • Nov 16
ZTS: Earnings Will Rebound As Volume Pressures Ease In 2026
Zoetis' analyst price target has been reduced from approximately $188 to $171 per share, as analysts cite tempered growth expectations and revised financial assumptions following recent quarterly updates. Analyst Commentary Following Zoetis' latest quarterly updates and subsequent guidance revision, analysts have updated their perspectives on the company's outlook.Anlatı Güncellemesi • Nov 01
ZTS: Global Demand Trends Will Drive Earnings Consistency In Coming Quarters
Narrative Update: Zoetis Analyst Price Target Adjustment Analysts have modestly decreased their price target for Zoetis from $165 to $158, citing a more cautious outlook ahead of upcoming results. Analyst Commentary Analyst perspectives on Zoetis highlight both optimism regarding the company’s long-term fundamentals as well as heightened caution leading into upcoming earnings releases.Anlatı Güncellemesi • Oct 18
Companion Animal And Livestock Demand Will Unlock Future Opportunities
Analysts have slightly lowered their price target for Zoetis from $189.22 to $188.83, citing modest revisions to revenue growth estimates. They also noted a marginal increase in expected profit margins.Anlatı Güncellemesi • Oct 04
Companion Animal And Livestock Demand Will Unlock Future Opportunities
Analysts have slightly lowered their price target for Zoetis from $190.29 to $189.22, citing marginally softer revenue growth and profit margin expectations. What's in the News Zoetis received conditional FDA approval for Dectomax-CA1, the first and only injectable for preventing and treating infestations caused by New World screwworm larvae in cattle.Seeking Alpha • Mar 25
Zoetis: Lots Of Growth Opportunities For This High-Quality Compounder
Summary Zoetis is currently cheap from a historical perspective, presenting a potential buying opportunity. The company operates in a growing animal healthcare market, benefiting from trends like pet humanization and medicalization, ensuring long-term growth. ZTS has a strong track record of market outperformance, impressive margins, and a high ROIC, making it a high-quality company. Despite the disappointing guidance for FY 2025 and the threat of possible competition, there are still plenty of growth opportunities in existing and untapped markets. Based on the earnings growth model, ZTS looks reasonably priced. Read the full article on Seeking AlphaSeeking Alpha • Mar 13
Zoetis: Focusing On The High Margin Segments
Summary The recent divestiture of the MFA segment improves margins and returns on capital. Zoetis is focusing on more profitable segments like genetics and companion animals. The recently updated Librela label includes adverse effects and urges practitioners to discuss potential adverse reactions with clients. I rate Zoetis as a buy, expecting a 10.3% investment rate of return, but I favor IDEXX for my portfolio. Read the full article on Seeking AlphaSeeking Alpha • Feb 13
Zoetis: In-Line Q4 Earnings And Weak Guidance Present A Buying Opportunity
Summary Zoetis' Q4 earnings met expectations, but the stock fell due to slowing growth and cautious 2025 guidance, presenting a buying opportunity around $163/share. Zoetis' unique advantages and pricing power in animal health, coupled with high R&D investment and a wide moat, make it a strong long-term play on emerging market growth. Despite regulatory risks and currency headwinds, Zoetis' dependable earnings and high operating margins justify a 12-month price target of $200/share. The company's diversified product portfolio and international presence position it well for sustained growth, particularly in the expanding pet care market. Read the full article on Seeking AlphaSeeking Alpha • Dec 26
The Wall Street Journal Vs. Zoetis
Summary The Wall Street Journal released an article claiming that Zoetis' OA pain drug (Librela) is not safe. I go over these claims and explain why I believe they are unfounded. Librela might face a label change soon, but I don't think there's any reason to worry. I explain why. Read the full article on Seeking AlphaSeeking Alpha • Dec 06
Zoetis: Are Competition And Price Increases A Cause For Concern?
Summary Zoetis is the market leader in a growing industry, and the numbers are starting to show its dominance. The company reported a very strong Q3 thanks to several growth drivers. Are competition and price increases a cause for concern? We discuss this in the article. Read the full article on Seeking AlphaSeeking Alpha • Nov 29
Zoetis: Healing Paws, Growing Profits
Summary Zoetis is active in multiple segments that are all expected to grow at a CAGR of 4% or more. The company has growing revenues, a strong balance sheet, a high FCF margin, and no major maturities. Librela, Solensia and Simparica Trio will drive the stock going forward. I estimate shares to be undervalued by approximately 16%. Read the full article on Seeking AlphaSeeking Alpha • Nov 18
Zoetis: This Beautifully Boring, Slow-Growing Compounder Is A Buy
Summary Zoetis, a leading animal health company, has shown impressive growth with a 17.55% CAGR since its IPO, outperforming the S&P 500. The company benefits from increasing global pet ownership and spending, making its revenues less susceptible to economic downturns. Zoetis boasts a strong competitive moat with a diverse product portfolio, significant patent protection, and consistent R&D investment. Despite trading at a premium, Zoetis' stable growth, robust market position, and low-risk profile make it a compelling long-term investment. Read the full article on Seeking AlphaHissedar Getirileri
| ZTS | US Pharmaceuticals | US Pazar | |
|---|---|---|---|
| 7D | 2.1% | 1.4% | 1.6% |
| 1Y | -52.4% | 48.6% | 18.6% |
Getiri vs. Endüstri: ZTS geçen yıl % 48.6 oranında getiri sağlayan US Pharmaceuticals sektörünün gerisinde kaldı.
Getiri vs Piyasa: ZTS geçen yıl % 18.6 oranında getiri sağlayan US Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| ZTS volatility | |
|---|---|
| ZTS Average Weekly Movement | 7.7% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
İstikrarlı Hisse Senedi Fiyatı: ZTS son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: ZTS 'nin haftalık oynaklığı ( 8% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2012 | 14,500 | Kristin Peck | www.zoetis.com |
Zoetis Inc. Amerika Birleşik Devletleri'nde ve uluslararası alanda hayvan sağlığı endüstrisi için ilaçların, aşıların, teşhis ürünlerinin ve hizmetlerinin, biyolojik cihazların, genetik testlerin ve hassas hayvan sağlığı çözümlerinin keşfi, geliştirilmesi, üretimi ve ticarileştirilmesi faaliyetlerini yürütmektedir. Şirket ürünlerini öncelikle köpekler, kediler ve atlardan oluşan refakatçi hayvanlar ve sığır, domuz, kümes hayvanları, balık ve koyun gibi çiftlik hayvanları da dahil olmak üzere türler arasında ticarileştirmektedir. Ayrıca parazit öldürücüler, aşılar, dermatoloji, anti-enfektifler, ağrı ve sedasyon, diğer farmasötikler ve hayvan sağlığı teşhisleri de sunmaktadır.
Zoetis Inc. Temel Bilgiler Özeti
| ZTS temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$31.36b |
| Kazançlar(TTM) | US$2.67b |
| Gelir(TTM) | US$9.53b |
11.7x
F/K Oranı3.3x
P/S OranıZTS aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| ZTS gelir tablosu (TTM) | |
|---|---|
| Gelir | US$9.53b |
| Gelir Maliyeti | US$2.68b |
| Brüt Kâr | US$6.85b |
| Diğer Giderler | US$4.18b |
| Kazançlar | US$2.67b |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
Aug 06, 2026
| Hisse başına kazanç (EPS) | 6.37 |
| Brüt Marj | 71.84% |
| Net Kâr Marjı | 28.03% |
| Borç/Özkaynak Oranı | 280.3% |
ZTS uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünTemettüler
2.8%
Mevcut Temettü Verimi33%
Ödeme OranıZTS güvenilir bir temettü ödüyor mu?
ZTS temettü geçmişine ve kıyaslamalara bakın| Zoetis temettü tari̇hleri̇ | |
|---|---|
| Eski Temettü Tarihi | Jul 20 2026 |
| Temettü Ödeme Tarihi | Sep 01 2026 |
| Eski temettüye kadar geçen günler | 13 days |
| Temettü ödeme tarihine kadar geçen günler | 56 days |
ZTS güvenilir bir temettü ödüyor mu?
ZTS temettü geçmişine ve kıyaslamalara bakınŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/06 17:52 |
| Gün Sonu Hisse Fiyatı | 2026/07/02 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Zoetis Inc. 39 Bu analistlerden 18, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Charles Butler | Barclays |
| Glen Santangelo | Barclays |